2Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy : reality and perspectives[ J~. Endocr Rev, 2000, 21 (2) :168-199.
3Metso S, Jaatinen P, Salmi J. Graves' disease [ J ]. N Engl J Med, 2008,359( 13 ) : 1408-1409.
4Mareocei C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glueoeortieoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy : results of a prospective, single-blind, randomized study[J]. J Clin Endocrinol Metab, 2001,86(8):.
5Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: systematic review and meta analysis[ Jl. J Clin Endocrinol Metab, 2009,94 (8) :2708-2716.
6Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO[ J]. Eur J Endocrinol, 2008, 158 (3) :273-285.
7Bartalena L, Baldeschi L, Dickinson A J, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy[ J]. Thyroid, 2008,18 (3) :333-346.
8Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity [ J 1. J Clin Endocrinol Metab, 2011,96 (2) :320-332.
9Bahn R. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now? [ J]. Thyroid, 2012,22 (1) :1-2.
10Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[ J]. J Clin Endocrinol Metab, 2004,89 ( 1 ) : 15-20.
